Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

171.59 -2.21 (-1.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
News headline image
1 Value Stock with Exciting Potential and 2 to Approach with Caution
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
From Biogen Inc.
Via GlobeNewswire
News headline image
What Does the Market Think About Biogen? ↗
 
Via Benzinga
News headline image
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing. 
Via Benzinga
News headline image
Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
News headline image
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version. 
Via Investor's Business Daily
News headline image
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen. 
Via Stocktwits
News headline image
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
From Biogen Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash. 
Via Stocktwits
Topics Government
News headline image
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗
Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio. 
Via Benzinga
News headline image
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗
The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space. 
Via Investor's Business Daily
Topics ETFs
News headline image
1 Profitable Stock with Exciting Potential and 2 to Avoid
A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care. 
Via Benzinga
News headline image
Demystifying Biogen: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
From Biogen Inc.
Via GlobeNewswire
News headline image
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
News headline image
Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
News headline image
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise 
From Biogen Inc.
Via GlobeNewswire
News headline image
What's going on in today's session: S&P500 movers ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
BIIB Q1 Earnings Call: New Product Growth Outpaces Declining MS Franchise Amid Lowered Guidance
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above... 
Via StockStory
Topics World Trade
News headline image
Only Half Of S&P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards? ↗
Only about 50% of S&P 500 stocks trade above their 200-day average, signaling narrow breadth even as the index rallies 22% since April. 
Via Benzinga
Topics Stocks
News headline image
3 Cash-Producing Stocks Skating on Thin Ice
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
News headline image
2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
4 Stocks to Buy for a Potential “Summer Panic” ↗
Luke Lango predicts a major event on May 7 will trigger a flood of cash – as much as $7 trillion – to rush back into U.S. stocks. It’s a catalyst that could change the entire market dynamic and create... 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.